Mimedx (MDXG) Receivables (2010 - 2026)
Mimedx recorded quarterly Receivables of $55.6 million in Q1 2026, down 26.6% quarter-over-quarter from $75.7 million in Q4 2025, and down 10.78% year-over-year from $62.3 million in Q1 2025.
Mimedx's Receivables history runs 17 years deep, the most recent figure standing at $55.6 million for Q1 2026.
- In Q1 2026, Receivables fell 10.78% year-over-year to $55.6 million; the TTM figure through Mar 2026 stood at $55.6 million (down 10.78% YoY), while the FY2025 annual figure was $75.7 million, up 28.4% from the prior year.
- Receivables came in at $55.6 million for Q1 2026 at Mimedx, down from $75.7 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $78.2 million in Q3 2025 to a low of $37.7 million in Q2 2022.
- A 5-year average of $54.5 million and a median of $53.9 million in 2023 frame the typical range for Receivables.
- Across the five-year window, Receivables jumped 44.71% in 2025 and declined 10.78% in 2026, its largest moves.
- Mimedx's Receivables stood at $43.1 million in 2022, then climbed by 25.04% to $53.9 million in 2023, then increased by 9.45% to $59.0 million in 2024, then gained by 28.4% to $75.7 million in 2025, then fell by 26.6% to $55.6 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $55.6 million, $75.7 million, and $78.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 55.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.57 Mn |
| Dec 31, 2025 | 75.71 Mn |
| Sep 30, 2025 | 78.19 Mn |
| Jun 30, 2025 | 73.17 Mn |
| Mar 31, 2025 | 62.29 Mn |
| Dec 31, 2024 | 58.96 Mn |
| Sep 30, 2024 | 54.03 Mn |
| Jun 30, 2024 | 52.80 Mn |
| Mar 31, 2024 | 57.02 Mn |
| Dec 31, 2023 | 53.87 Mn |
| Sep 30, 2023 | 49.01 Mn |
| Jun 30, 2023 | 51.16 Mn |
| Mar 31, 2023 | 44.69 Mn |
| Dec 31, 2022 | 43.08 Mn |
| Sep 30, 2022 | 40.83 Mn |
| Jun 30, 2022 | 37.66 Mn |
| Mar 31, 2022 | 37.67 Mn |
| Dec 31, 2021 | 40.35 Mn |
| Sep 30, 2021 | 36.54 Mn |
| Jun 30, 2021 | 37.64 Mn |
| Mar 31, 2021 | 36.12 Mn |
| Dec 31, 2020 | 36.36 Mn |
| Sep 30, 2020 | 33.04 Mn |
| Jun 30, 2020 | 30.10 Mn |
| Mar 31, 2020 | 32.53 Mn |
| Dec 31, 2019 | 33.59 Mn |
| Sep 30, 2019 | 23.80 Mn |
| Dec 31, 2018 | 55.30 Mn |
| Dec 31, 2017 | 70.70 Mn |
| Sep 30, 2017 | 59.58 Mn |
| Jun 30, 2017 | 60.74 Mn |
| Mar 31, 2017 | 66.85 Mn |
| Dec 31, 2016 | 1.93 Mn |
| Sep 30, 2016 | 63.43 Mn |
| Jun 30, 2016 | 54.86 Mn |
| Mar 31, 2016 | 53.88 Mn |
| Dec 31, 2015 | 53.76 Mn |
| Sep 30, 2015 | 46.78 Mn |
| Jun 30, 2015 | 39.45 Mn |
| Mar 31, 2015 | 31.00 Mn |
| Dec 31, 2014 | 26.67 Mn |
| Sep 30, 2014 | 23.30 Mn |
| Jun 30, 2014 | 20.50 Mn |
| Mar 31, 2014 | 18.97 Mn |
| Dec 31, 2013 | 16.09 Mn |
| Sep 30, 2013 | 13.71 Mn |
| Jun 30, 2013 | 11.76 Mn |
| Mar 31, 2013 | 9.82 Mn |
| Dec 31, 2012 | 7.65 Mn |
| Sep 30, 2012 | 6.17 Mn |
| Jun 30, 2012 | 3.95 Mn |
| Mar 31, 2012 | 2.85 Mn |
| Dec 31, 2011 | 1.89 Mn |
| Sep 30, 2011 | 1.50 Mn |
| Jun 30, 2011 | 1.21 Mn |
| Dec 31, 2010 | 162,376.00 |